Single agent versus combination chemotherapy for metastatic breast cancer (Q24241459)

title

Single agent versus combination chemotherapy for metastatic breast cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6885070&resulttype=core&format=json

13 May 2020

main subject

chemotherapy

0 references

metastatic breast cancer

1 reference

6

0 references

Davina Ghersi

4

0 references

Charlene Thornton

object named as

Charlene E Thornton

3

0 references

author name string

Sue Carrick

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6885070&resulttype=core&format=json

13 May 2020

Sharon Parker

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6885070&resulttype=core&format=json

13 May 2020

John Simes

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6885070&resulttype=core&format=json

13 May 2020

Charlene E Thornton

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6885070&resulttype=core&format=json

13 May 2020

Davina Ghersi

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6885070&resulttype=core&format=json

13 May 2020

Nicholas Wilcken

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6885070&resulttype=core&format=json

Cochrane Database of Systematic Reviews

13 May 2020

publication date

15 April 2009

0 references

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6885070&resulttype=core&format=json

13 May 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6885070&resulttype=core&format=json

13 May 2020

page(s)

CD003372

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6885070&resulttype=core&format=json

The effect on survival of initial chemotherapy in advanced breast cancer: polychemotherapy versus single drug

13 May 2020

cites work

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003372.PUB3

Time to progression in metastatic breast cancer patients treated with epirubicin is not improved by the addition of either cisplatin or lonidamine: final results of a phase III study with a factorial design

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003372.PUB3

Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003372.PUB3

Docetaxel vs 5-fluorouracil plus vinorelbine in metastatic breast cancer after anthracycline therapy failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003372.PUB3

Combination chemotherapy for metastatic breast carcinoma. Prospective comparison of multiple drug therapy with L-phenylalanine mustard

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003372.PUB3

Phase III study of intravenous vinorelbine in combination with epirubicin versus epirubicin alone in patients with advanced breast cancer: a Scandinavian Breast Group Trial (SBG9403).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003372.PUB3

Survival of premenopausal women with metastatic breast cancer. Long-term follow-up of Eastern Cooperative Group and Cancer and Leukemia Group B studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003372.PUB3

Improved remission rates and remission duration in young women with metastatic breast cancer following combined oophorectomy and chemotherapy. A study by cancer and leukemia group B

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003372.PUB3

A daily diary for quality of life measurement in advanced breast cancer trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003372.PUB3

Combination or mild single agent chemotherapy for advanced breast cancer? CMF vs epirubicin measuring quality of life.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003372.PUB3

A prospective randomized trial comparing epirubicin monochemotherapy to two fluorouracil, cyclophosphamide, and epirubicin regimens differing in epirubicin dose in advanced breast cancer patients. The French Epirubicin Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003372.PUB3

Is first-line single-agent mitoxantrone in the treatment of high-risk metastatic breast cancer patients as effective as combination chemotherapy? No difference in survival but higher quality of life were found in a multicenter randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003372.PUB3

Cisplatin plus oral etoposide (EoP) combination is more effective than paclitaxel in patients with advanced breast cancer pretreated with anthracyclines: a randomised phase III trial of Turkish Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003372.PUB3

Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003372.PUB3

Epirubicin or epirubicin and cisplatin as first-line therapy in advanced breast cancer. A phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003372.PUB3

Epirubicin or epirubicin and vindesine in advanced breast cancer. A phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003372.PUB3

Phase III comparative study of vinorelbine combined with doxorubicin versus doxorubicin alone in disseminated metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA8.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003372.PUB3

Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003372.PUB3

Survival benefit with capecitabine/docetaxel versus docetaxel alone: analysis of therapy in a randomized phase III trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003372.PUB3

Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003372.PUB3

Chemotherapy of advanced breast cancer: a controlled randomized trial of cyclophosphamide versus a four-drug combination

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003372.PUB3

Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003372.PUB3

Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003372.PUB3

A comparative study of PALA, PALA plus 5-FU, and 5-FU in advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003372.PUB3

Second and subsequent lines of chemotherapy for metastatic breast cancer: what did we learn in the last two decades?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003372.PUB3

Achievements in systemic therapies in the pregenomic era in metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003372.PUB3

Evidence for the use of chemotherapy in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003372.PUB3

Treatment for anthracycline-pretreated metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003372.PUB3

Extending survival with chemotherapy in metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003372.PUB3

Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003372.PUB3

Goals of treatment for patients with metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003372.PUB3

Systematic reviews of chemotherapy and endocrine therapy in metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003372.PUB3

Chemotherapy alone versus endocrine therapy alone for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003372.PUB3

Beta blockade during and after myocardial infarction: an overview of the randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003372.PUB3

Single agent versus combination chemotherapy for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003372.PUB3

Sequential single-agent chemotherapy for metastatic breast cancer: therapeutic nihilism or realism?

21 January 2018

1 reference

12 December 2020

Docetaxel and paclitaxel in the treatment of breast cancer: a review of clinical experience

1 reference

12 December 2020

A phase 2 evaluation of 1-(2-chloroethyl)-3-(4- methylcyclohexyl)-1-nitrosourea (NSC 95441) in patients with advanced breast cancer.

1 reference

12 December 2020

Combination chemotherapy and adriamycin in patients with advanced breast cancer. A Southwest Oncology Group study

1 reference

12 December 2020

Evaluation of VP-16 and the combination of adriamycin and vincristine in advanced breast cancer

1 reference

12 December 2020

[A double-blind randomized comparative study of oral 5-fluorouracil (5-FU), cyclophosphamide (CPA), and 5-FU CPA in advanced breast cancer]

1 reference

12 December 2020

VP-16 adriamycin vs. adriamycin alone in advanced adenocarcinoma of the breast, phase II, a randomized trial: a Southwest Oncology Group Study

1 reference

12 December 2020

Evaluation of single-drug versus multiple-drug chemotherapy in the treatment of advanced breast cancer

1 reference

12 December 2020

Applications of dose intensity to problems in chemotherapy of breast and colorectal cancer.

1 reference

12 December 2020

Adriamycin alone or combined with vincristine in the treatment of advanced breast cancer

1 reference

12 December 2020

Practical methods for incorporating summary time-to-event data into meta-analysis

1 reference

12 December 2020

Controlled evaluation of adriamycin (NSC-123127) in patients with disseminated breast cancer

1 reference

12 December 2020

Refractory Breast Cancer: A Comparison of Two Different Chemotherapy Regimens

1 reference

12 December 2020

Randomized trial of doxorubicin alone or combined with vincristine and mitomycin C in women with metastatic breast cancer.

1 reference

12 December 2020

Phase II study of hexamethylmelamine alone and in combination with mitomycin C and vincristine in advanced breast carcinoma

1 reference

12 December 2020

Combination chemotherapy for metastatic breast cancer: reaching for the cure

1 reference

12 December 2020

Single-drug vs combination cytotoxic chemotherapy in advanced breast cancer: a randomized study

1 reference

12 December 2020

Combination chemotherapy for metastatic breast cancer: comparison of multiple drug therapy with 5-fluorouracil, cytoxan and prednisone with adriamycin or adrenalectomy

1 reference

12 December 2020

Combination chemotherapy versus single-agent therapy as first- and second-line treatment in metastatic breast cancer: a prospective randomized trial

1 reference

12 December 2020

Dynamic hormonal chemotherapy in advanced metastatic breast carcinoma

1 reference

12 December 2020

A double blind comparative study of tegafur (FT) and UFT (a combination of Tegafur and uracil) in advanced breast cancer.

1 reference

12 December 2020

Is salvage chemotherapy for metastatic breast cancer always effective and well tolerated? A phase II randomized trial of vinorelbine versus 5-fluorouracil plus leucovorin versus combination of mitoxantrone, 5-fluorouracil plus leucovorin

1 reference

12 December 2020

Current management of advanced breast cancer

1 reference

12 December 2020

Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women

1 reference

12 December 2020

Weekly adriamycin versus VAC in advanced breast cancer. A randomized trial

1 reference

12 December 2020

Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial

1 reference

12 December 2020

Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group

1 reference

12 December 2020

Phase II clinical trial of isophosphamide (NSC-109724) in patients with advances breast cancer

1 reference

12 December 2020

Doxorubicin versus mitomycin versus doxorubicin plus mitomycin in advanced breast cancer: a randomized study

1 reference

12 December 2020

Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment

1 reference

12 December 2020

Randomized clinical trial of doxorubicin alone or combined with mitolactol in women with advanced breast cancer and prior chemotherapy exposure

1 reference

12 December 2020

10.1002/14651858.CD003372.PUB3

Identifiers

DOI

2 references

Consolidated OpenCitations Corpus – April 2017

2694217

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6885070&resulttype=core&format=json

13 May 2020

2694217

1 reference

Consolidated OpenCitations Corpus – April 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6885070&resulttype=core&format=json

13 May 2020

PubMed publication ID

19370586

2 references

Consolidated OpenCitations Corpus – April 2017

2694217